v3.26.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenues $ 819 $ 420
Cost of revenues 63 42
Gross profit 756 378
Operating expenses    
Selling, general and administrative 12,075 11,349
Research and development 862 272
Acquired in-process research and development 1,967 0
Loss on impairment of intangible assets 6,995 0
Total operating expenses 21,899 11,621
Operating loss (21,143) (11,243)
Other income (expenses), net    
Interest income 34 81
Change in fair value of royalties payable due to related parties 5,709 (2,239)
Change in fair value of convertible notes payable 2 0
Loss on debt extinguishment (3,260) 0
Net loss on trading debt securities (564) 0
Other expenses, net (2) (10)
Total other income (expenses), net 1,638 (2,259)
Loss from operations before income tax provision (benefit) (19,505) (13,502)
Income tax provision (benefit) (1,810) 3,141
Net loss (17,695) (16,643)
Less: Net loss attributable to non-controlling interest (512) 0
Net loss attributable to Catheter Precision, Inc. (17,183) (16,643)
Deemed dividend on warrant inducement offer 0 (5,158)
Net loss attributable to Catheter Precision, Inc. common stockholders $ (17,183) $ (21,801)
Net loss per share attributable to Catheter Precision, Inc. common stockholders, basic and diluted (in dollars per share) $ (15.9) $ (126.91)
Weighted-average common shares used in computing net loss per share, basic and diluted (in shares) 1,080,617 171,774
Nonrelated Party [Member]    
Other income (expenses), net    
Interest expense $ (95) $ (10)
Related Party [Member]    
Other income (expenses), net    
Interest expense (186) (81)
Product [Member]    
Revenues $ 819 $ 420